Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.
Elucidation of the mechanism of action of the HCV NS5B polymerase thumb site II inhibitors has presented a challenge. Current opinion holds that these allosteric inhibitors stabilize the closed, inactive enzyme conformation, but how this inhibition is accomplished mechanistically is not well underst...
Guardado en:
Autores principales: | Sarah E Boyce, Neeraj Tirunagari, Anita Niedziela-Majka, Jason Perry, Melanie Wong, Elaine Kan, Leanna Lagpacan, Ona Barauskas, Magdeleine Hung, Martijn Fenaux, Todd Appleby, William J Watkins, Uli Schmitz, Roman Sakowicz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/511db7137be1485baa683530d590daed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
por: Christy M Hebner, et al.
Publicado: (2012) -
Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
por: R V Sriram Uday, et al.
Publicado: (2021) -
Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.
por: Assaf Shapira, et al.
Publicado: (2011) -
Effects of Lower Temperature on Expression and Biochemical Characteristics of HCV NS3 Antigen Recombinant Protein
por: Chen-Ji Huang, et al.
Publicado: (2021) -
First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Zahra Hasanshahi, et al.
Publicado: (2021)